<DOC>
	<DOCNO>NCT01234935</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give dasatinib together gemcitabine hydrochloride effective gemcitabine hydrochloride alone treat pancreatic cancer . PURPOSE : This randomized phase II trial study well give dasatinib together gemcitabine hydrochloride work compare give gemcitabine hydrochloride alone treat patient pancreatic cancer previously treat surgery .</brief_summary>
	<brief_title>Dasatinib Gemcitabine Hydrochloride Gemcitabine Hydrochloride Alone Treating Patients With Pancreatic Cancer Previously Treated With Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare disease-free survival 18 month dasatinib-gemcitabine combination therapy single-agent gemcitabine . SECONDARY OBJECTIVES : I . To evaluate effect disease-free survival dasatinib-gemcitabine combination therapy compare gemcitabine alone adjuvant treatment resect pancreatic adenocarcinoma . II . To evaluate effect overall survival dasatinib-gemcitabine combination therapy compare gemcitabine alone adjuvant treatment resect pancreatic adenocarcinoma . III . To evaluate tolerability safety two arm . IV . To identify potential biological correlate associate clinical benefit dasatinib-gemcitabine combination therapy compare gemcitabine alone . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive gemcitabine hydrochloride IV day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . ARM II : Patients receive gemcitabine hydrochloride IV day 1 , 8 , 15 oral dasatinib daily day 1-28 . Treatment repeat every 28 day 6 courses* absence disease progression unacceptable toxicity . NOTE : * Courses dasatinib repeat every 28 day 1 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Acinar Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Written inform consent begin protocol specify procedure Histologically proven pancreatic adenocarcinoma Any T , N , M0 disease gross disease resect ( R0 R1 resection ) ECOG Performance status index 0 1 Absolute Neutrophils &gt; = 1.5 x 10^9/L Platelets &gt; = 100 x 10^9/L Hemoglobin &gt; = 10 g/dL Total bilirubin = &lt; 2.0 x UNL ; subject Gilbert 's syndrome , confirm genotyping invader UGTIA1 molecular assay study entry must total bilirubin &lt; 3 x UNL ASAT ( SGOT ) ALAT ( SGPT ) = &lt; 2.5 x UNL Alkaline Phosphatase = &lt; 5 x UNL Creatinine &lt; 1.5 x UNL Serum Na , K+ , Magnesium , Phosphate Calcium &gt; = LNL First study treatment must give within 60 day surgery within 7 day randomization Patients must accessible treatment followup compliant study procedure Negative pregnancy test ( urine serum ) within 7 day first study treatment woman childbearing potential , also must implement adequate nonhormonal contraceptive measure study treatment least 3 month last dose study therapy Ability take oral medication ( dasatinib must swallow whole ) Prior concurrent systemic anticancer therapy ( immunotherapy , hormonal therapy , biological therapy , chemotherapy ) pancreatic cancer Prior concurrent radiation therapy pancreatic cancer Pregnant lactating patient M1 pancreatic cancer Concurrent congestive heart failure , unstable angina pectoris , M1 within 6 month first study treatment Uncontrolled hypertension highrisk uncontrolled arrhythmias Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , torsades de pointes ) Diagnosed suspected congenital long QT syndrome Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) History significant neurologic psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent Past current history neoplasm pancreatic adenocarcinoma , except : curatively treat nonmelanoma skin cancer ; situ carcinoma cervix ; cancer curatively treat evidence disease least 1 year Concurrent treatment experimental drug treatment investigational drug within 30 day first study treatment Currently receive drug know significant CYP 3A4 inhibitory effect ( ketoconazole , itraconazole , troleandomycin , erythromycin , diltiazem , verapamil , ritonavir , indinavir ) Concurrent administration inducer CYP 3A4 may result low exposure dasatinib therefore allow ( e.g. , phenytoin , carbamazepine , rifampicin , phenobarbital , pentobarbital , St John 's Wort ) Known allergy reaction dasatinib gemcitabine excipients use study History significant bleeding disorder unrelated cancer , include : diagnosed congenital bleeding disorder ( e.g. , Von Willebrand 's disease ) ; diagnose acquire bleed disorder within 1 year ( e.g. , acquire antifactor VIII antibody ) ; ongoing recent ( = &lt; 3 month ) significant gastrointestinal bleeding Patients currently take drug generally accept risk cause Torsades De Pointes include : quinidine , procainamide , disopyramide ; amiodarone , sotalol , ibutilide , dofetilide ; erythromycin , clarithromycin ; chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide ; cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine Concurrent treatment intravenous bisphosphonates ; prior treatment stop least 2 week first dose study treatment Concurrent medical condition may increase risk toxicity , include pleural pericardial effusion grade Active uncontrolled infection require parenteral antimicrobial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>